Reprint
Outcomes and Therapeutic Management of Bladder Cancer
Edited by
September 2020
120 pages
- ISBN978-3-03936-934-8 (Hardback)
- ISBN978-3-03936-935-5 (PDF)
This book is a reprint of the Special Issue Outcomes and Therapeutic Management of Bladder Cancer that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
Format
- Hardback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
bladder cancer; robotic-assisted; open; radical cystectomy; survival; propensity score; bladder cancer; age; urothelial carcinoma; radical cystectomy; outcome; survival; anesthesia recovery periods; bladder cancer; cognitive impairment; gamma-cyclodextrins; neuromuscular blockade; robotic radical cystectomy; glycogen; clear-cell adenocarcinoma; urinary bladder; SEER program database; bladder cancer; female; intracorporeal neobladder; outcomes; radical cystectomy; robotic; sex-sparing; bladder cancer; methylation; biomarkers; FOXA1; GATA3; KRT20; molecular markers; mRNA; muscle-invasive bladder cancer; PCR; urothelial carcinoma; human epidermal growth factor receptor 2; indoleamine 2,3-dioxygenase; programmed death ligand-1; urothelial carcinoma; urinary bladder; immunotherapy; bladder cancer; nodal disease; pN1; radical cystectomy; neoadjuvant; adjuvant; chemotherapy; n/a